| Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP P Pregno, A Chiappella, M Bellò, B Botto, S Ferrero, S Franceschetti, ... Blood, The Journal of the American Society of Hematology 119 (9), 2066-2073, 2012 | 284 | 2012 |
| First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an … U Vitolo, A Chiappella, AJM Ferreri, M Martelli, I Baldi, M Balzarotti, ... Journal of Clinical Oncology 29 (20), 2766-2772, 2011 | 271 | 2011 |
| Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial U Vitolo, A Chiappella, S Franceschetti, AM Carella, I Baldi, G Inghirami, ... The Lancet Oncology 15 (7), 730-737, 2014 | 210* | 2014 |
| ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma GS Nowakowski, A Chiappella, RD Gascoyne, DW Scott, Q Zhang, ... Journal of Clinical Oncology 39 (12), 1317-1328, 2021 | 185 | 2021 |
| Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi L Arcaini, D Vallisa, S Rattotti, VV Ferretti, AJM Ferreri, P Bernuzzi, ... Annals of Oncology 25 (7), 1404-1410, 2014 | 173 | 2014 |
| Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final … A Chiappella, M Martelli, E Angelucci, E Brusamolino, A Evangelista, ... The Lancet Oncology 18 (8), 1076-1088, 2017 | 145 | 2017 |
| Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi C Visco, A Chiappella, L Nassi, C Patti, S Ferrero, D Barbero, ... The Lancet Haematology 4 (1), e15-e23, 2017 | 144 | 2017 |
| Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network CY Cheah, A George, E Giné, A Chiappella, HC Kluin-Nelemans, ... Annals of Oncology 24 (8), 2119-2123, 2013 | 138 | 2013 |
| Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin … E Pelosi, P Pregno, D Penna, D Deandreis, A Chiappella, G Limerutti, ... La radiologia medica 113 (4), 578-590, 2008 | 137 | 2008 |
| Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 D Rossi, S Rasi, S Franceschetti, D Capello, A Castelli, L De Paoli, ... Leukemia 23 (6), 1118-1126, 2009 | 136 | 2009 |
| Epigenomic evolution in diffuse large B-cell lymphomas H Pan, Y Jiang, M Boi, F Tabbò, D Redmond, K Nie, M Ladetto, ... Nature communications 6 (1), 6921, 2015 | 125 | 2015 |
| Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study PL Zinzani, V Stefoni, E Finolezzi, E Brusamolino, MG Cabras, ... Clinical Lymphoma and Myeloma 9 (5), 381-385, 2009 | 117 | 2009 |
| Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue S Ciavarella, MC Vegliante, M Fabbri, S De Summa, F Melle, G Motta, ... Annals of Oncology 29 (12), 2363-2370, 2018 | 113 | 2018 |
| A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma TE Witzig, GS Nowakowski, TM Habermann, A Goy, ... Annals of Oncology 26 (8), 1667-1677, 2015 | 108 | 2015 |
| ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma GS Nowakowski, A Chiappella, TE Witzig, M Spina, RD Gascoyne, ... Future oncology 12 (13), 1553-1563, 2016 | 107 | 2016 |
| ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B … U Vitolo, TE Witzig, RD Gascoyne, DW Scott, Q Zhang, W Jurczak, ... Hematological Oncology 37, 36-37, 2019 | 106 | 2019 |
| Nonpegylated liposomal doxorubicin (Myocet™) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 … S Luminari, A Montanini, D Caballero, S Bologna, M Notter, MJS Dyer, ... Annals of Oncology 21 (7), 1492-1499, 2010 | 106 | 2010 |
| Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial PL Zinzani, C Pellegrini, A Chiappella, A Di Rocco, F Salvi, MG Cabras, ... Blood, The Journal of the American Society of Hematology 129 (16), 2328-2330, 2017 | 100 | 2017 |
| Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program M Ladetto, C Lobetti-Bodoni, B Mantoan, M Ceccarelli, C Boccomini, ... Blood, The Journal of the American Society of Hematology 122 (23), 3759-3766, 2013 | 100 | 2013 |
| Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a … U Vitolo, A Chiappella, E Angelucci, G Rossi, AM Liberati, MG Cabras, ... haematologica 94 (9), 1250, 2009 | 93 | 2009 |
